ABB Azipod® Electric Propulsion Can Save $1.7 Million in Fuel Costs Annually, Study Shows
An independent study by marine consultancy Deltamarin revealed that the ABB Azipod® electric propulsion system for ferries could save up to $1.7 million in annual fuel costs per vessel, strengthening Azipod® propulsion’s market-leading position in sustainable marine technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005120/en/
The latest addition to the Azipod® propulsor family, the mid-range Azipod® series.
By simulating a transit on seven existing ferry routes, researchers found that a ferry equipped with twin 10 MW mid-power range Azipod® units consumed less fuel compared to a similar vessel powered by a traditional shaftline propulsion system. Lower fuel consumption also means that the Azipod®-powered ferry would reduce CO2 emissions – by approximately 10,000 tons per year. This is equivalent to the amount of carbon dioxide emitted by about 2,200 passenger cars annually.
The global ferry industry, which transports 2.1 billion passengers every year, according to trade association Interferry, is facing increased pressure to meet the International Maritime Organization’s target of reducing annual emissions by 30 percent by 2025.
To help ferries improve energy efficiency and lower emissions, ABB is launching a new series of mid-power range Azipod® propulsion systems in June 2019. The latest Azipod® series will be available in the 7.5 to 14.5 MW power range and will fill the gap between the low and high-power range of Azipod® propulsors already in the market.
“We are continuously strengthening our portfolio of electric, digital and connected solutions that maximize the potential of ships and ultimately enable more sustainable operations,” said Peter Terwiesch, President of the Industrial Automation business at ABB, which offers solutions for a wide range of industries, including marine. “With the launch of the mid-power range Azipod® propulsion, we will be able to empower more shipowners to improve the performance of their vessels while lowering environmental impact.”
The Azipod® propulsion system, where the electric drive motor is in a submerged pod outside the ship hull, can rotate 360 degrees to increase maneuverability and operating efficiency, and has a proven ability to cut fuel consumption by up to 20 percent compared to traditional shaftline propulsion systems. Due to minimal noise and vibration, Azipod® propulsion also improves passenger and crew comfort. Azipod® propulsion systems have accumulated more than 15 million running hours, saving over 700,000 tons of fuel in the passenger cruise segment alone.
The latest Azipod® ‘M’ series is equipped with ABB’s fourth generation permanent magnet motors that draw on proven Azipod® propulsion technologies and have been refined to further increase power and maximize efficiency. The design simplicity of the system provides increased robustness and reliability, at the same time allowing for ease of maintenance.
With this expansion, the Azipod® propulsion family now covers the power range of 1-22 MW and is available for vessels from smaller crafts to icebreakers capable of independently operating in the harshest conditions. In addition to ferries and RoPax vessels that carry both vehicles and passengers, the mid-power range will also be applicable for larger offshore construction vessels, midsize cruise ships and shuttle tankers.
ABB – one of the world’s leading enablers of sustainable transportation – has already received several breakthrough orders in the ferry segment, including an Azipod® propulsion system for an LNG-powered Viking Line vessel due for delivery next year. Azipod® propulsion was also preferred by Finnish shipping company Wasaline for a recently ordered dual-fuel and battery power ferry, which will operate between Sweden and Finland.
“Building a future-proof, robust RoPax ferry requires proven technology that enables energy efficiency, saves valuable onboard space and provides increased passenger comfort. These features, coupled with superior maneuverability that would allow the ferry to operate a precise schedule crucial for a busy route, have made ABB’s Azipod® propulsion a natural choice for our newbuild project,” – said Peter Ståhlberg, CEO of Wasaline.
With over half of its global revenue generated from solutions that directly address the causes of climate change, ABB is at the forefront of sustainable development.
To watch the video, click here .
A summary of the Deltamarin study can be found here .
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005120/en/
Contact information
ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland
Media Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom